430 related articles for article (PubMed ID: 33771856)
1. Facts and Hopes in Multiple Myeloma Immunotherapy.
Sperling AS; Anderson KC
Clin Cancer Res; 2021 Aug; 27(16):4468-4477. PubMed ID: 33771856
[TBL] [Abstract][Full Text] [Related]
2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunoediting and immune dysregulation in multiple myeloma.
Nakamura K; Smyth MJ; Martinet L
Blood; 2020 Dec; 136(24):2731-2740. PubMed ID: 32645135
[TBL] [Abstract][Full Text] [Related]
4. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
Neri P; Bahlis NJ; Lonial S
Clin Cancer Res; 2016 Dec; 22(24):5959-5965. PubMed ID: 27797968
[TBL] [Abstract][Full Text] [Related]
5. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
Clin Cancer Res; 2020 Apr; 26(7):1541-1554. PubMed ID: 31672768
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for the treatment of multiple myeloma.
Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
[TBL] [Abstract][Full Text] [Related]
7. Is immunotherapy here to stay in multiple myeloma?
Rodríguez-Otero P; Paiva B; Engelhardt M; Prósper F; San Miguel JF
Haematologica; 2017 Mar; 102(3):423-432. PubMed ID: 28082344
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
Pianko MJ; Moskowitz AJ; Lesokhin AM
Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972
[TBL] [Abstract][Full Text] [Related]
9. Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.
Lee SJ; Borrello I
Cancer Treat Res; 2016; 169():207-225. PubMed ID: 27696265
[TBL] [Abstract][Full Text] [Related]
10. Advances in immunotherapy in multiple myeloma.
Boussi L; Niesvizky R
Curr Opin Oncol; 2017 Nov; 29(6):460-466. PubMed ID: 28877078
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
12. Immune therapy in multiple myeloma.
Luptakova K; Avigan D
Clin Adv Hematol Oncol; 2015 Nov; 13(11):767-75. PubMed ID: 27058703
[TBL] [Abstract][Full Text] [Related]
13. Cellular immunotherapy in multiple myeloma.
Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
[TBL] [Abstract][Full Text] [Related]
14. Cellular immunotherapy in multiple myeloma: lessons from preclinical models.
Binsfeld M; Fostier K; Muller J; Baron F; Schots R; Beguin Y; Heusschen R; Caers J
Biochim Biophys Acta; 2014 Dec; 1846(2):392-404. PubMed ID: 25109893
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy strategies in multiple myeloma.
Bae J; Munshi NC; Anderson KC
Hematol Oncol Clin North Am; 2014 Oct; 28(5):927-43. PubMed ID: 25212890
[TBL] [Abstract][Full Text] [Related]
17. Metabolic approaches to rescue antitumor Vγ9Vδ2 T-cell functions in myeloma.
Castella B; Riganti C; Massaia M
Front Biosci (Landmark Ed); 2020 Jan; 25(1):69-105. PubMed ID: 31585878
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for multiple myeloma: Current status and future directions.
Ayed AO; Chang LJ; Moreb JS
Crit Rev Oncol Hematol; 2015 Dec; 96(3):399-412. PubMed ID: 26153389
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in multiple myeloma: when, where, and for who?
Verkleij CPM; Korst CLBM; van de Donk NWCJ
Curr Opin Oncol; 2020 Nov; 32(6):664-671. PubMed ID: 32852308
[TBL] [Abstract][Full Text] [Related]
20. Translating the anti-myeloma activity of Natural Killer cells into clinical application.
Fionda C; Stabile H; Molfetta R; Soriani A; Bernardini G; Zingoni A; Gismondi A; Paolini R; Cippitelli M; Santoni A
Cancer Treat Rev; 2018 Nov; 70():255-264. PubMed ID: 30326421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
